Insider Trading Alert - IP, CYBX And JAZZ Traded By Insiders

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

Yesterday, March 5, 2014, 233 U.S. common stocks issued filings of shares being bought or sold by insiders. The transactions ranged in value from $57.59 to $85,937,500.00.

Highlighted Stocks Traded by Insiders:

International Paper (IP) - FREE Research Report

Ealy Carleton C who is Senior Vice President at International Paper sold 10,000 shares at $48.35 on March 5, 2014. Following this transaction, the Senior Vice President owned 105,934 shares meaning that the stake was reduced by 8.63% with the 10,000-share transaction.

The shares most recently traded at $48.60, up $0.25, or 0.51% since the insider transaction. Historical insider transactions for International Paper go as follows:

  • 4-Week # shares sold: 36,201
  • 12-Week # shares sold: 46,201
  • 24-Week # shares sold: 76,201

The average volume for International Paper has been 3.6 million shares per day over the past 30 days. International Paper has a market cap of $21.2 billion and is part of the consumer goods sector and consumer non-durables industry. Shares are down 1.65% year-to-date as of the close of trading on Wednesday.

International Paper Company operates as a paper and packaging company in North America, Europe, Latin America, Russia, Asia, and North Africa. The stock currently has a dividend yield of 2.9%. The company has a P/E ratio of 16.0. Currently there are 9 analysts that rate International Paper a buy, no analysts rate it a sell, and 2 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on IP - FREE

TheStreet Quant Ratings rates International Paper as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, notable return on equity, good cash flow from operations, impressive record of earnings per share growth and compelling growth in net income. We feel these strengths outweigh the fact that the company has had generally high debt management risk by most measures that we evaluated. Get the full International Paper Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

Cyberonics (CYBX) - FREE Research Report

Wise David S who is SR VP & Chief Admin Officer at Cyberonics sold 2,000 shares at $67.58 on March 5, 2014. Following this transaction, the SR VP & Chief Admin Officer owned 77,055 shares meaning that the stake was reduced by 2.53% with the 2,000-share transaction.

The shares most recently traded at $67.65, up $0.07, or 0.11% since the insider transaction. Historical insider transactions for Cyberonics go as follows:

  • 4-Week # shares sold: 12,895
  • 12-Week # shares sold: 28,895
  • 24-Week # shares sold: 64,411

The average volume for Cyberonics has been 251,700 shares per day over the past 30 days. Cyberonics has a market cap of $1.9 billion and is part of the health care sector and health services industry. Shares are up 7.23% year-to-date as of the close of trading on Wednesday.

Cyberonics, Inc., together with its subsidiaries, engages in the design, development, marketing, and sale of implantable medical devices to hospitals and ambulatory surgery centers. The company has a P/E ratio of 40.3. Currently there are 7 analysts that rate Cyberonics a buy, no analysts rate it a sell, and 1 rates it a hold.

Exclusive Offer: Get the latest Stock Analysis on CYBX - FREE

TheStreet Quant Ratings rates Cyberonics as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, largely solid financial position with reasonable debt levels by most measures, growth in earnings per share, increase in net income and solid stock price performance. We feel these strengths outweigh the fact that the company is trading at a premium valuation based on our review of its current price compared to such things as earnings and book value. Get the full Cyberonics Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

Jazz Pharmaceuticals (JAZZ) - FREE Research Report

Mulligan Seamus who is Director at Jazz Pharmaceuticals sold 550,000 shares at $156.25 on March 5, 2014. Following this transaction, the Director owned 1.5 million shares meaning that the stake was reduced by 27.42% with the 550,000-share transaction.

The shares most recently traded at $151.75, down $4.50, or 2.97% since the insider transaction. Historical insider transactions for Jazz Pharmaceuticals go as follows:

  • 4-Week # shares sold: 2,000
  • 12-Week # shares sold: 4,000
  • 24-Week # shares sold: 17,000

The average volume for Jazz Pharmaceuticals has been 1.1 million shares per day over the past 30 days. Jazz Pharmaceuticals has a market cap of $9.3 billion and is part of the health care sector and drugs industry. Shares are up 26.99% year-to-date as of the close of trading on Wednesday.

Jazz Pharmaceuticals Public Limited Company, a specialty biopharmaceutical company, engages in the identification, development, and commercialization of pharmaceutical products for various medical needs in the United States, Europe, and other countries. The company has a P/E ratio of 45.8. Currently there are 10 analysts that rate Jazz Pharmaceuticals a buy, no analysts rate it a sell, and 1 rates it a hold.

Exclusive Offer: Get the latest Stock Analysis on JAZZ - FREE

TheStreet Quant Ratings rates Jazz Pharmaceuticals as a buy. The company's strengths can be seen in multiple areas, such as its robust revenue growth, largely solid financial position with reasonable debt levels by most measures, notable return on equity, expanding profit margins and good cash flow from operations. We feel these strengths outweigh the fact that the company is trading at a premium valuation based on our review of its current price compared to such things as earnings and book value. Get the full Jazz Pharmaceuticals Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

null

More from Markets

3 Must Reads on the Market From TheStreet's Top Columnists

3 Must Reads on the Market From TheStreet's Top Columnists

Purdue Pharma Unloads Sales Staff, Transitioning From Painkiller Focus

Purdue Pharma Unloads Sales Staff, Transitioning From Painkiller Focus

Dow Finishes Lower as Nasdaq Posts New Record

Dow Finishes Lower as Nasdaq Posts New Record

Airlines Rebuke Trump Policy of Separating Children

Airlines Rebuke Trump Policy of Separating Children

Deutsche Bank Fined $205 Million Over Currency-Trading Violations

Deutsche Bank Fined $205 Million Over Currency-Trading Violations